Replimune Group (REPL) to Release Quarterly Earnings on Wednesday

Replimune Group (NASDAQ:REPL) is expected to be issuing its Q3 2026 results before the market opens on Wednesday, February 11th. Analysts expect Replimune Group to post earnings of ($0.85) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Tuesday, February 3, 2026 at 8:00 AM ET.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.08. On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Replimune Group Stock Up 5.9%

REPL stock opened at $7.38 on Wednesday. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average of $8.94 and a two-hundred day moving average of $7.22. Replimune Group has a 12 month low of $2.68 and a 12 month high of $14.80. The company has a market cap of $578.89 million, a price-to-earnings ratio of -2.13 and a beta of 0.73.

Insider Activity at Replimune Group

In other Replimune Group news, Director Kapil Dhingra sold 3,169 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Sarchi sold 5,208 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $9.10, for a total transaction of $47,392.80. Following the completion of the sale, the insider directly owned 123,088 shares in the company, valued at $1,120,100.80. This trade represents a 4.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 25,625 shares of company stock worth $257,607. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Replimune Group by 17.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after buying an additional 6,653 shares during the period. Millennium Management LLC grew its position in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after acquiring an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after purchasing an additional 119,145 shares during the period. Rhumbline Advisers increased its stake in Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after purchasing an additional 6,616 shares during the period. Finally, Sei Investments Co. lifted its position in shares of Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock worth $283,000 after purchasing an additional 18,263 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and increased their price target for the company from $3.00 to $13.00 in a report on Monday, October 20th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $4.00 to $18.00 in a research note on Monday, October 20th. HC Wainwright upgraded Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. upgraded shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price objective for the company in a research report on Monday, October 20th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.75.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.